Trial Profile
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Alisertib (Primary)
- Indications Acute myeloid leukaemia; Ewing's sarcoma; Germ cell and embryonal neoplasms; Germ cell cancer; Liver cancer; Neuroblastoma; Osteosarcoma; Precursor cell lymphoblastic leukaemia-lymphoma; Rhabdoid tumour; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Urogenital cancer; Wilms' tumour
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 25 Aug 2021 Results of a population pharmacokinetic and exposure-safety analyses of alisertib in children enrolled in two clinical trials (NCT02444884 and NCT01154816) published in the Journal of Clinical Pharmacology
- 18 Feb 2019 Results evaluating efficacy of alisertib in pediatric patients with refractory or recurrent solid tumors or acute leukemias published in the Clinical Cancer Research
- 21 Sep 2017 Status changed from active, no longer recruiting to completed.